211 related articles for article (PubMed ID: 36291159)
1. USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1.
Lin YT; Lin J; Liu YE; Chen YC; Liu ST; Hsu KW; Chen DR; Wu HT
Cells; 2022 Oct; 11(20):. PubMed ID: 36291159
[TBL] [Abstract][Full Text] [Related]
2. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1.
Yi J; Li H; Chu B; Kon N; Hu X; Hu J; Xiong Y; Kaniskan HU; Jin J; Gu W
Cell Death Differ; 2023 Jul; 30(7):1799-1810. PubMed ID: 37291217
[TBL] [Abstract][Full Text] [Related]
4. Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers.
Abd El-Aziz YS; Spillane AJ; Jansson PJ; Sahni S
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33543229
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis.
Xia X; Liao Y; Huang C; Liu Y; He J; Shao Z; Jiang L; Dou QP; Liu J; Huang H
Cancer Lett; 2019 Nov; 465():118-128. PubMed ID: 31518603
[TBL] [Abstract][Full Text] [Related]
6. G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance.
Blake A; Dragan M; Tirona RG; Hardy DB; Brackstone M; Tuck AB; Babwah AV; Bhattacharya M
Sci Rep; 2017 Apr; 7():46525. PubMed ID: 28422142
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.
Carreira LD; Oliveira RI; Moreira VM; Salvador JAR
Expert Opin Ther Targets; 2023; 27(11):1043-1058. PubMed ID: 37789645
[TBL] [Abstract][Full Text] [Related]
8.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
9. Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer.
Wang H; Li JM; Wei W; Yang R; Chen D; Ma XD; Jiang GM; Wang BL
Cancer Sci; 2020 Jan; 111(1):84-97. PubMed ID: 31774615
[TBL] [Abstract][Full Text] [Related]
10. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.
Chen W; Qin Y; Wang D; Zhou L; Liu Y; Chen S; Yin L; Xiao Y; Yao XH; Yang X; Ma W; Chen W; He X; Zhang L; Yang Q; Bian X; Shao ZM; Liu S
PLoS Biol; 2018 Jul; 16(7):e2005869. PubMed ID: 30052635
[TBL] [Abstract][Full Text] [Related]
11.
Chen Z; Wu L; Zhou J; Lin X; Peng Y; Ge L; Chiang CM; Huang H; Wang H; He W
Theranostics; 2020; 10(8):3382-3396. PubMed ID: 32206097
[No Abstract] [Full Text] [Related]
12. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
13. A feedforward circuit shaped by ECT2 and USP7 contributes to breast carcinogenesis.
Zhang Q; Cao C; Gong W; Bao K; Wang Q; Wang Y; Bi L; Ma S; Zhao J; Liu L; Tian S; Zhang K; Yang J; Yao Z; Song N; Shi L
Theranostics; 2020; 10(23):10769-10790. PubMed ID: 32929379
[No Abstract] [Full Text] [Related]
14. YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2.
Wu A; Wang X; Zhang F; Yang X; Quan Y; Dong J; Lai Y; Yang D; Sun J; Wang M
Mol Carcinog; 2024 Mar; 63(3):417-429. PubMed ID: 37983722
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1.
Guan T; Yang X; Liang H; Chen J; Chen Y; Zhu Y; Liu T
J Cell Physiol; 2022 Jul; 237(7):2992-3000. PubMed ID: 35506169
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
17. TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2-mediated glycolysis.
Xu H; Li L; Dong B; Lu J; Zhou K; Yin X; Sun H
Cancer Med; 2023 Oct; 12(19):19807-19820. PubMed ID: 37746908
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
19. BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation.
Li S; Wu H; Huang X; Jian Y; Kong L; Xu H; Ouyang Y; Chen X; Wu G; Yu L; Wang X
J Pathol; 2021 Jul; 254(3):265-278. PubMed ID: 33797754
[TBL] [Abstract][Full Text] [Related]
20. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
